CHENGDU, China, Oct. 20, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor receptor 2 (HER2)-directed ADC trastuzumab botidotin (also known as A166) trastuzumab botidotin versus trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic BC was presented as an oral report by Professor Xichun Hu from Fudan University Shanghai Cancer Center (Presentation # LBA2
The first "GPS + Laser" hybrid rangefinder redefining how golfers see and play the game. CITY OF INDUSTRY, Calif., Oct. 20, 2025 -- MILESEEY Golf proudly announces that its groundbreaking hybrid rangefinder, the GenePro G1, has been featured in TIME's "The Best Inventions of 2025: Special Mentions."Recognized for its innovative integration of AMOLED full-color touchscreen and built-in global course mapping, the GenePro G1 stands out as a true "GPS + Laser" hybrid that brings a smarter, faster, and more intuitive experience to every golfer's round.&
CHENGDU, China, Oct. 20, 2025 -- A news report from CNS: Recently, a wave of discerning homebuyers from different cities has been converging on Chengdu CATANIA. International elites from New York, London, Tokyo, Singapore, Hong Kong, Vancouver, and other world-class major cities have found a common ground in Chengdu. The global acclaim for Chengdu CATANIA goes far beyond a simple purchase. It is an affirmation of its international standing. This recognition stems from its core advantages—an unrivaled location, top-tier amenities, and a deeply integrated art gene. These q
SUZHOU, China, Oct. 20, 2025 -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the indication of monotherapy for the treatment of HER2-positive advanced colorectal cancer (CRC) in patients who have failed prior treatments with oxaliplatin, fluorouracil and irino
SUZHOU, China, Oct. 20, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colorectal cancer (mCRC), along with the confirmatory study design of the phase III study of JSKN003 versus physician's choice of chemotherapy in platinum-resistant ovarian cancer (PROC) were presented as posters at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) from October 17 to 21, 2025,
A Joyful, Design-led Partnership to Celebrate the Festive Season HONG KONG, Oct. 20, 2025 -- This festive season, 1664 is excited to announce its first-ever festive artist collaboration across Hong Kong, mainland China, Singapore, Malaysia, and Vietnam with celebrated French artist Camille Walala. Bringing a modern twist to the traditional holiday season that encapsulates Christmas and Lunar New Year, 1664 will be introducing limited-edition designs and upbeat experiences from October 2025 onwards. This partnership exemplifies Carlsberg Group's strategy to transform convivial m
[ 메디채널 김장윤(JASON KIM) 기자 ] - Global campaign celebrates the U.S. debut of the movie-inspired collaboration package - NEW YORK, Oct. 20, 2025 -- Nongshim carried out a global campaign at New York Times Square to celebrate the launch of Shin Ramyun in collaboration with Netflix's hit animated film 'KPop Demon Hunters'. As known for "The Crossroads of the World" and attracting over 450,000 visitors daily, Times Square served as the stage for global consumers to directly taste and enjoy the Shin Ramyun brand through a variety of interactive activities that seamlessly connected
CHENGDU, China, Oct. 20, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Z
SHANGHAI, Oct. 20, 2025 -- Approved by the State Council, the 2025 Sustainable Global Leaders Conference opened on October 16 in Huangpu District, Shanghai. Centered around the theme "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth," the Conference brings together global wisdom and strength to explore new pathways for sustainable development, injecting powerful "Chinese dynamism" into global sustainable governance. The Conference is jointly organized by the World Green Design Organization (WGDO) and Sina Group, co-organ
BEIJING, Oct. 20, 2025 -- The annual conference of Financial Street Forum 2025 will be held on October 27-30 in Beijing. Over 400 delegates from more than 30 countries and regions will join the four-day conference, introduced by an official of the organizing committee of the forum at a press briefing here on Friday. This year's conference will include a main forum and several parallel forums, discussing topics on international and domestic economic situation and financial supervision, international financial governance and cooperation, high-quality financial opening up and how t